Dr. Bourhis on the Rationale to Explore Debio 1143 in Head and Neck Cancer

Video

Jean Bourhis, MD, PhD, Radiation Oncology, Centre Hospitalier Universitaire Vaudois, discusses the rationale to explore Debio 1143 in patients with head and neck cancer.

Jean Bourhis, MD, PhD, Radiation Oncology, Centre Hospitalier Universitaire Vaudois, discusses the rationale to explore Debio 1143 in patients with head and neck cancer.

The current standard of care for patients with locally advanced squamous cell carcinoma of the head and neck is concurrent chemoradiation. However, a subset of these patients have a high risk of relapse, says Bourhis. Once patients relapse, there are limited treatment options available. Given this high unmet clinical need, researchers sought to evaluate the addition of Debio 1143 to concurrent high-dose cisplatin and chemoradiation as a way to overcome resistance to chemoradiation.

In preclinical models, Debio 1143 had shown promising antitumor activity in combination with cisplatin and radiation, says Bourhis. Accordingly, investigators launched a phase I/II trial (NCT02022098), in which the recommended phase II dose of Debio 1143 was compared with placebo in combination with concurrent chemoradiation.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute